Vienna, February 22, 2021 – a:head bio AG today closed a second round of financing to fuel its revolutionary approach in combating neurological disorders.
After securing more than EUR 4 million of private and public funding in 2019, a:head today closed another 7-digit EUR equity round with a consortium of investors including red stars.com data AG, the company’s seed investor.
‘The fresh capital will enable us to strengthen and broaden our efforts in CNS disease modeling and support the development of a human organoid-based screening engine’, says Oliver Szolar, CEO of a:head. ‘Our goal is to recreate human brain disorders in the lab to set new, unprecedented standards for the design of working therapies for patients.’
‘We at red-stars have been supporting the development of a:head from its inception and are fascinated about the company’s progress’, says Thomas Streimelweger, CEO of red-stars and a:head’s Chairman of the Supervisory Board. ‘After our initial engagement, we decided to top up our investment to provide the company with additional resources to accelerate the speed to reach its ambitious objectives’.
In late 2022, a:head plans a series A financing round to prepare the company for its next growth phase, and already reaches out to interested venture capital firms active in the field of neuroscience and 3D biology.